ART Advanced Research Technologies Inc.
TSX : ARA

ART Advanced Research Technologies Inc.

March 21, 2007 17:21 ET

ART Advanced Research Technologies Announces Q4 2006 and FY2006 Financial Results Conference Call

MONTREAL, QUEBEC--(CCNMatthews - March 21, 2007) - ART Advanced Research Technologies Inc. (TSX:ARA) ("ART"), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, invites you to participate in a conference call to discuss the company's financial results for the fourth quarter and the year ended December 31, 2006. The conference call will follow the press release issued earlier on the same day, and will be held on:

Friday, March 23, 2007

8:30 a.m. (EDT)

To participate in the conference call when dialing within the Montreal area, please dial (514) 868-2590, or (866) 898-9626 for the rest of North America. Outside of North America, please dial (514) 868-2590. Participants are asked to dial 10 minutes prior to the start time.

The conference call will feature Sebastien Gignac, President and Chief Executive Officer, and Jacques Bedard, Chief Financial Officer.

A replay of the conference call will be available until March 30, 2007. To listen to the replay from the Montreal area, please dial (514) 861-2272, or, (800) 408-3053 for the rest of North America. From outside of North America, please dial (514) 861-2272. The access code for the replay is 3217900#.

We look forward to your participation and thank you for your interest in ART Advanced Research Technologies Inc.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. eXplore Optix™, an optical molecular imaging device designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is distributed by GE Healthcare and is used by industry and academic leaders worldwide. SoftScan®, an optical medical imaging device, is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra™ line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca .

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the Management Proxy Circular of ART dated October 24, 2006, available on SEDAR (www.sedar.com) under the profile of "ART Advanced Research Technologies Inc. (old)" (ART's predecessor issuer).

Contact Information